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The SCY1-like 1 binding protein 1 (SCYL1-BP1) protein was identiﬁed as an interacting partner of E3
ligase p53-induced RING H2 protein (Pirh2) and mouse double minute gene number 2 (MDM2) by
yeast two-hybrid screening. Further investigation suggested there are two interactions involved
in different mechanisms. SCYL1-BP1 can be ubiquitinated and degraded by Pirh2 but not by
MDM2, which suggests that SCYL1-BP1 can be regulated by Pirh2. On the other hand, while
SCYL1-BP1 binds to ubiquitin E3 ligase MDM2, it promotes MDM2 self-ubiquitination and results
in a reduction of MDM2 protein level.
Structured summary:
MINT-7904819, MINT-7904837, MINT-7904806, MINT-7904715: MDM2 (uniprotkb:Q00987) physically
interacts (MI:0915) with SCYL1-BP1 (uniprotkb:Q5T7V8) by anti tag coimmunoprecipitation (MI:0007)
MINT-7904857, MINT-7904899: SCYL1-BP1 (uniprotkb:Q5T7V8) physically interacts (MI:0915) with
MDM2 (uniprotkb:Q00987) by anti bait coimmunoprecipitation (MI:0006)
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Mouse double minute gene number 2 (MDM2) is involved in
cell growth and differentiation through its interaction with other
cellular proteins. The MDM2 protein level is increased in a signiﬁ-
cant number of human tumors such as soft tissue sarcomas, oste-
osarcomas and breast tumors, underscoring its pivotal
involvement in the development of human cancer [3]. MDM2 be-
longs to the family of RING Finger ubiquitin ligases [11], and the
principal function of MDM2 is to mediate the ubiquitination and
proteasome-dependent degradation of the p53 tumor suppressor
protein and other growth regulatory proteins [9]. Accordingly,
the ligase activity of MDM2 can be abolished by mutation of either
one of eight cysteine and histidine residues involved in zinc coor-
dination within the RING ﬁnger domain. Besides p53, MDM2 alsochemical Societies. Published by E
tein; MDM2, mouse double
, SCY1-like 1 binding protein 1
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, TX 78245, USA. Fax: +1 210
tory of Genetic Engineering,
hina. Fax: +86 21 55664526.
@fudan.edu.cn (K. Huo).ubiquitinates Numb [18], b-arrestin binding protein [16], histone
acetyltransferase Tip60 [13] as well as MDM2 itself.
SCY1-like 1 binding protein 1 (SCYL1-BP1), as we previously re-
ported [6], is a highly conserved, widely expressed protein that
binds to a p53-induced protein, p53-induced RING H2 protein
(Pirh2) [19]. Like MDM2, Pirh2 is also an E3 enzyme involved in
an auto-regulatory feedback loop with p53. Then we indentiﬁed
the binding between SCYL1-BP1 and MDM2, which forced us to
ask questions like: Is SCYL1-BP1 the substrate of Pirh2, MDM2 or
both? Can SCYL1-BP1 reversely affect Pirh2 or MDM2? And we
found out SCYL1-BP1 was only a substrate of Pirh2, however could
not be ubiquitinated or degraded by MDM2. Interestingly, by inter-
action with MDM2, SCYL1-BP1 promoted MDM2 self-ubiquitina-
tion and induced MDM2 protein degradation.2. Materials and methods
2.1. Plasmids
Human SCYL1-BP1 cDNA [6] was derived from human fetal liver
cDNA library (Clontech) and cloned into pCMV-Myc (Stratagene),
pEGFPc-1 (Clontech) and pGEX-5x-1 (Pharmacia Biotech) vectors
respectively. The Myc-tagged full length and depletion mutantslsevier B.V. All rights reserved.
Fig. 1. Interaction of SCYL1-BP1 and MDM2 in vitro and in vivo. (A) SCYL1-BP1
bound to MDM2 in HEK293 cells. HEK293 cells were co-transfected with plasmids
expressing GFP-SCYL1-BP1 and Myc-MDM2. Immunoprecipitates prepared by anti-
Myc or anti-GFP antibody plus protein-G-agarose, then analysed by Western blot
using anti-GFP or anti-Myc antibodies as indicated, as well as the cell lysates (10%
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the pCMV-Myc vectors. The primers used were P1, P2 for the full
length of MDM2; P1 and P3 for the MDM2DC1; P1 and P4 for
the MDM2DC2; P5: and P2 for the MDM2DN1; P6 and P2 for the
MDM2DN2; P7 and P2 for the MDM2DN3; P6 and P4 for MDM2-
155-321 truncated mutation. Myc-Pirh2 expression plasmid was
cloned by inserting full-length of Pirh2 cDNA into the pCMV-Myc
vector (Table 1).
2.2. Cell culture and transfection
The study employed sk-hep1 (p53 wt), HepG2 (p53 wt), Hep3B
(p53 null), H1299 (p53 null) and HEK293 cells. DNA transfection
was carried out using Lipofectamine2000 according to the manu-
facturer’s instruction. p53 and MDM2 double knockout MEFs
(2KO-MEFs) cells were gifts from Dr. G. Lozano [14].
2.3. Antibodies
The primary antibodies used for immunoprecipitation or Wes-
tern Blotting were as follows: rabbit polyclonal anti-Myc antibody
(Santa Cruz), mouse monoclonal anti-GFP (Santa Cruz), mouse
monoclonal anti-p53 (DO-7, Abcam), rabbit polyclonal anti-p53
phosphorylated on Ser15 (pS15p53, Cell Signaling Technology)
and mouse monoclonal anti-MDM2 (1B10, Novocatra). The anti-
SCYL1-BP1 anti-serum was generated by using puriﬁed His-tagged
full-length SCYL1-BP1 protein as an antigen.
2.4. In vivo ubiquitylation assays
Cells plated in 100 mm plate were transfected with combina-
tions plasmids as indicated in the ﬁgure legends. To inhibit protea-
some-mediated protein degradation, the cells were treated with
30 lM proteasome inhibitor MG132 (Calbiochem) for 6 h before
harvest. Cells were harvested at 48 h after transfection from each
plate and separated into two aliquots: one was for immunoblotting
and the other for ubiquitination assays. Cell pellets were lysed in
RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1%
SDS, 50 mM Tris–HCl, pH 7.5, 1 mM PMSF, 10 lg/ml aprotinin,
5 mg/ml leupeptin). The lysates were sonicated on ice and clariﬁed
through centrifugation followed by incubation with Ni-NTA beads
at room temperature for 4 h. The bound proteins were washed
three times with RIPA buffer and eluted by boiling for 5 min in pro-
tein sample buffer (200 mM imidazole, 0.15 M Tris–HCl (pH 6.7),
30% glycerol, 0.72 M b-mercaptoethanol, and 5% SDS). The eluted
proteins were analyzed by immunoblot with indicated antibodies.
2.5. Co-immunoprecipitation assay
For co-immunoprecipitation assay between exogenous SCYL1-
BP1 and MDM2, HEK293 cells were co-transfected with pEGFP-
SCYL1-BP1 and pCMV-Myc-MDM2 plasmids. Cell extracts were
prepared with lysis buffer (50 mM Tris–HCl (pH 7.5), 150 mMNaCl,
0.1% NP-40, 5 mM EDTA, 5 mM EGTA, 15 mM MgCl2, 60 mM b-Table 1
Primers used in this study.
Name Sequence (50–30)
P1 GGCCATACGGCCATGTGCAATACCAACATGTCTGTACC
P2 GGCCGAGGCGGCCCTAGGGGAAATAAGTTAGCACAATCAT
P3 GGCCGAGGCGGCCCTAAGGTTCAATGGCATTAAGGGGC
P4 GGCCGAGGCGGCCCTATCTGTTGCAATGTGATGGAAG
P5 GGCCATTACGGCCTGAAAGAGGTTCTTTTTTATCTTGGC
P6 GGCCGAGGCGGCCCTATCTGTTGCAATGTGATGGAAG
P7 GGCCATTACGGCCTGTTGGGCCCTTCGTGAGAATTglycerophosphate, 0.1 mM sodium orthovanadate, 0.1 mM NaF,
0.1 mM benzamide, 10 lg/ml aprotinin, 10 lg/ml leupeptin,
1 mM PMSF), followed by incubation with anti-Myc antibodies.
Precipitated proteins were analyzed by immunoblot with anti-
GFP antibodies.
To detect the protein–protein interaction between endogenous
SCYL1-BP1 and MDM2, sk-hep1 cells were lysed in the same lysis
buffer as mentioned before. And the lysates were incubated with
mouse IgG or anti-MDM2 antibodies, precipitated proteins were
detected by SCYL1-BP1 anti-serum.
3. Results
3.1. SCYL1-BP1 binds to MDM2 both in vivo and in vitro
To examine the interaction between SCYL1-BP1 and MDM2, we
co-transfected HEK293 cells with plasmids expressing Myc-tagged
MDM2 and GFP-tagged SCYL1-BP1, and performed co-immunopre-
cipitation assay. As expected, MDM2 can be co-immunoprecipi-
tated with SCYL1-BP1 (Fig. 1A). This interaction was further
conﬁrmed by co-immunoprecipitation of endogenous SCYL1-BP1
with endogenous MDM2 from sk-hep1 cell lysates (Fig. 1C).
Co-immunoprecipitation of MDM2 and GFP-SCYL1-BP1 was also
observed in a p53 deﬁcient H1299 cells, indicating that their inter-input). (B) SCYL1-BP1 interacted with MDM2 in the absence of p53. H1299 cells
were co-transfected with plasmids expressing Myc-SCYL1-BP1 and GFP-MDM2.
Lysates (10% input) and immunoprecipitates prepared by anti-Myc or anti-GFP
antibodies with protein-G-agarose were analyzed by Western blot using indicated
antibodies. (C) Endogenous SCYL1-BP1 interacted with MDM2 in sk-hep1 cells.
Lysates from sk-hep1 cells were split into two parts. One were immunoprecipitated
with mouse immunoglobulin G (IgG), monoclonal anti-MDM2 antibody or anti-BP1
anti-serum then detected by anti-SCYL1-BP1 anti-serum; another one were
immunoprecipitated by rabbit IgG, anti-BP1 anti-serum, or monoclonal anti-
MDM2 antibody, and then detected by anti-MDM2 antibodies. (D) SCYL1-BP1
bound to MDM2 in vitro. MDM2 protein (purchased from Bostonchem) was
incubated with beads containing GST-GFP or GST-SCYL1-BP1. Following binding 3 h
in room temperature and extensive washing, the beads-bound material was
analyzed by Western blot using anti-MDM2 and anti-GST antibodies. MDM2 alone
and GST-SCYL1-BP1 alone were used as controls. (*Indicated unspeciﬁc band.)
Fig. 3. SCYL1-BP1 was a ubiquitination substrate of Pirh2 but not MDM2’s
substrate. (A) Only Pirh2 induced the degradation of SCYL1-BP1. GFP-SCYL1-BP1,
Myc-Pirh2 and Myc-MDM2 plasmids were transfected into HEK293 cells as
indicated. Before harvest, cells were treated with 50 lg/ml CHX for 0, 1, 2, 4 h.
Then cell lysates were assayed for SCYL1-BP1 and GAPDH. (B) SCYL1-BP1 was
ubiquitinated by Pirh2 but not MDM2.HEK293 cells were co-transfected with
plasmids HA-ub, GFP-SCYL1-BP1 and Myc-Pirh2 or Myc-MDM2(C), cultured in the
presence (+) or absence () of 30 lM MG132 6 h before harvest. The ubiquitinated
conjugates puriﬁed by anti-GFP antibody combined with protein G agarose beads
were analyzed by anti-HA antibodies. Cell lysates (10% input) were detected by
Western blot using the indicated antibodies.
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down experiments using puriﬁed GST-SCYL1-BP1 and MDM2 pro-
tein demonstrated a direct interaction of SCYL1-BP1 with MDM2
in vitro (Fig. 1D).
After establishing the in vivo and in vitro interaction between
MDM2 and SCYL1-BP1 we decided to deﬁne the minimal interac-
tion domain onMDM2. A diagram illustrating the known structural
motifs within MDM2 is shown in Fig. 2A. When full length MDM2
and a series of MDM2 deletion derivatives were used to assess the
interaction with SCYL1-BP1, only the MDM2-N3 (322-491aa) trun-
cation mutant failed to associate detectably with SCYL1-BP1 in the
co-immunoprecipitation experiments (Fig. 2B). Thus, we con-
cluded that the region of MDM2 necessary for binding to SCYL1-
BP1 might reside on the amino acid residues 155-321 comprising
the central acidic domain of MDM2. Then we made the clone
(Myc-MDM2-155-321), tested the binding of this truncation mu-
tant to GFP-SCYL1-BP1. The result showed that indeed SCYL1-BP1
directly bound to this central acidic resided region of MDM2
(Fig. 2C).
3.2. SCYL1-BP1 is a substrate of Pirh2 but not MDM2
Since SCYL1-BP1 interacts with both MDM2 and Pirh2, two well
characterized RING-ﬁnger-domain E3s that can ubiquitinate and
degrade p53 independently, it appears reasonable to suspect that
SCYL1-BP1 may be the substrate of MDM2 and/or Pirh2. To test
this idea, we co-transfected HEK293 cells with SCYL1-BP1 and
Pirh2 or MDM2, and monitored the protein level of SCYL1-BP1.
As shown in Fig. 3A, a fast degradation of SCYL1-BP1 was observed
with the co-transfection of Pirh2, but not with the co-transfection
of MDM2, suggesting that SCYL1-BP1 may be a substrate of Pirh2
E3 ligase in vivo. To conﬁrm this premise, HEK293 cells were co-
transfected with Myc-tagged pirh2, GFP-tagged SCYL1-BP1 andFig. 2. SCYL1-BP1 bound to the central acidic domain of MDM2. (A) Region of
MDM2 necessary for binding to SCYL1-BP1. Various MDM2 mutants were
expressed in HEK293 cells. (+) and () indicate presence and absence, respectively,
of binding. Top row is schematic structure of wild-type MDM2 (modiﬁed from
Michael and Oren, 2003). (B) SCYL1-BP1 failed to bind to the MDM2 mutant lack of
the central acidic region. GFP-SCYL1-BP1 alone (lane 1) or with series of Myc-tagged
MDM2 mutants were transfected into HEK293 cells. Cell lysates were immuno-
precipitated with anti-Myc antibody, followed by WB with anti-GFP antibody. (C)
SCYL1-BP1 bound directly to the 155–321aa region of MDM2. GFP-SCYL1-BP1 and
myc-MDM2-155-321 expression plasmids were transfected into HEK293 cells as
indicated. Cell lysates were immunoprecipitated with anti-Myc antibody, followed
by WB with anti-GFP antibody.HA-tagged ubiquitin, after cells were lysed, the immunoprecipi-
tates by anti-GFP antibody were blotted with anti-HA antibody.
Consistent with the degradation data, SCYL1-BP1 was indeed ubiq-
uitinated with co-transfection of Pirh2, but not MDM2 (Fig. 3B and
C). Together, our results strongly suggest that Pirh2, but not
MDM2, functions as the ubiquitin ligase of SCYL1-BP1 and medi-
ates its degradation.
3.3. SCYL1-BP1 promoted proteasome-dependant down-regulation
and self-ubiquitination of MDM2
In the co-immunoprecipitation study of MDM2/SCYL1-BP1
interaction, we unexpectedly encountered the striking observation
that the protein level of MDM2 was signiﬁcantly depleted when
co-expressed with SCYL1-BP1 (Fig. 1B comparing lane 1 and 3).
To conﬁrm this result, MDM2 protein level was monitored in
HepG2 cells co-transfected with MDM2 plasmid and incremental
amount of SCYL1-BP1 plasmid. As expected, a decrease of MDM2
level was observed with the increase of SCYL1-BP1 expression
(Fig. 4A). A similar phenotype was also observed in p53 deﬁcient
H1299 cells, indicating that this interplay between MDM2 and
SCYL1-BP1 is p53-independent (Fig. 4B). Interestingly, this
SCYL1-BP1-mediated reduction of MDM2 was partially rescued
by treating the cells with proteasome inhibitor, MG132, suggesting
that MDM2 is degraded through ubiquitin-proteasome pathway
(Fig. 4C). Given the self-ubiquitination activity of MDM2, we car-
ried out a cell-based ubiquitination assay to examine the effect
of SCYL1-BP1 on MDM2 self-ubiquitination. As shown in Fig. 4D,
co-transfection of SCYL1-BP1 led to a decrease of MDM2, and con-
comitantly stimulated the ubiquitination pattern of MDM2 in 2KO-
MEFs cells. Therefore, we concluded that SCYL1-BP1 promoted
MDM2 degradation through proteasome pathway by stimulating
its self-ubiquitination.
Fig. 4. SCYL1-BP1 promoted mdm2 degradation by activating mdm2 auto-ubiqui-
tination. (A) HepG2 (B) H1299 cells were transfected with increasing amount of
GFP-SCYL1-BP1 plasmid, when required, cells were treated with 30 lM MG132 for
6 h before harvest. Cell lysates were assayed for MDM2, GFP-SCYL1-BP1 and
GAPDH. (C) SCYL1-BP1 regulated MDM2 proteasomal degradation. H1299 cells
were transfected with Myc-MDM2 and SCYL1-BP1 plasmids and then treated with
or without MG132 as indicated. Cell lysates were assayed for MDM2, GFP-SCYL1-
BP1 and GAPDH. (D) SCYL1-BP1 promotes MDM2 auto-ubiquitination in 2KO-MEFs
cells. Lysates prepared from 2KO-MEFs cells transfected with the plasmids
expressing His-Ub, Myc-MDM2 and GFP-SCYL1-BP1 plasmids were incubated with
Ni-NTA-agarose. The precipitates were analyzed for ubiquitinated MDM2 using
monoclonal anti-MDM2. Total lysates (10%) were analyzed for MDM2, SCYL1-BP1
and GAPDH.
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Previously we used SCY1-like 1 (SCYL1) (also known as NTKL) as
the bait to screen for its binding partners and identiﬁed SCYL1-BP1,
a soluble protein highly conserved and widely expressed in many
tissues. SCYL1-BP1 was also reported to interact with Rad6 and
suggested to be a golgin by Hennies et al. [10]. And we also ob-
served some aberrant expressions of some key cancer marker
genes in our Human Cancer cDNA Expression Array assay (data
not shown). But what exact function SCLY1-BP1 executes in vivo,
by what kind of mechanism and through which pathway are still
under research in our lab.
Following up our previous studies, here we show that SCYL-BP1
can bind to two RING ﬁnger E3:Pirh2 [19] and MDM2. Unlike p53,
which is a common ubiquitination substrate of both Pirh2 and
MDM2, SCYL1-BP is only degraded and ubiquitinated by Pirh2.
However, by binding to MDM2, SCYL1-BP1 promotes the self-ubiq-
uitination and degradation of MDM2. Recently growing numbers of
MDM2 binding proteins have been reported, including nucleolar
proteins (e.g. B23 [12] and C23 [15]), ribosomal proteins (e.g.
ARF [17], S7 [2], L5 [4], NS [5] etc.) and centrosomal protein
(Lat2 [1]). Interestingly, C23 shares several similar properties with
SCYL1-BP1, such as binding to the center acidic region of MDM2,
possessing a coiled-coil domain and impairing MDM2 protein le-
vel. It was also reported that C23 interacted with p53 when cells
were subjected to genotoxic stress [15]. However, in our experi-
ments we failed to detect any stable association between SCYL1-
BP1 and p53 (data not shown), suggesting that SCYL1-BP1 and
p53 bind to MDM2 asynchronously.
The different response of SCYL1-BP1 to MDM2 and Pirh2 is
interesting. In the paper by Duan et al., they listed several differ-ences between Pirh2 and MDM2, and suggested that Pirh2 pro-
motes ubiquitination of p53 in an MDM2-independent manner
[8]. It was also reported that increasing level of Pirh2 could reduce
the tumor suppression function of p53 in the lung tumor cells [7].
As it appears critical for the cells to determine when, where and
using which ubiquitin E3 to degrade p53 under different circum-
stances, the research on SCYL1-BP1 may provide us further clues
on this regulation.
Acknowledgements
We thank Dr. G. Lozano for p53 and MDM2 double knockout
MEFs (2KO) cells. We also thank Dr. Jianxin Gu for his advice and
great help on this paper.
This work is supported by grants from the Chinese 863 program
(2006AA02A310) and Shanghai Science and Technology Develop-
ing Program (Grant No. 03DZ14024) to K. Huo.
Reference
[1] Aylon, Y., Shmueli, A., Yabuta, N., Nojima, H. and Oren, M. (2006) A positive
feedback loop between the p53 and Lats2 tumor suppressors prevents
tetraploidization. Genes Dev. 20, 687–700.
[2] Chen, D., Zhang, Z., Li, M., Wang, W., Li, Y., Rayburn, E.R., Hill, D.L., Wang, H. and
Zhang, R. (2007) Ribosomal protein S7 as a novel modulator of p53-MDM2
interaction: binding to MDM2, stabilization of p53 protein, and activation of
p53 function. Oncogene 26, 5029–5037.
[3] Cordon-Cardo, C., Latres, E., Drobnjak, M., Oliva, M.R., Pollack, D., et al. (1994)
Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas.
Cancer Res. 54, 794–799.
[4] Dai, M.S. and Lu, H. (2004) Inhibition of MDM2-mediated p53 ubiquitination
and degradation by ribosomal protein L5. J. Biol. Chem. 279, 44475–44482.
[5] Dai, M.S., Sun, X. and Lu, H. (2008) Aberrant expression of nucleostemin
activates p53 and induces cell cycle arrest via inhibition of MDM2. Mol. Cell.
Biol. 28, 4365–4376.
[6] Di, Y., Li, J., Fang, D., Xu, Z., He, X., Zhang, X., et al. (2003) Cloning and
characterization of a novel gene which encodes a protein interacting with the
mitosis associated kinase-like protein NTKL. J. Hum. Genet. 48, 315–321.
[7] Duan, W., Gao, L., Druhan, L.J., Zhu, W., Morrison, C., et al. (2004) Expression of
Pirh2, a newly identiﬁed ubiquitin protein ligase, in lung cancer. J. Natl. Cancer
Inst. 96, 1718–1721.
[8] Duan, W., Gao, L., Wu, X., Zhang, Y., Otterson, G.A., et al. (2006) Differential
response between the p53 ubiquitin protein ligases Pirh2 and MdM2 following
DNA damage in human cancer cells. Exp. Cell Res. 312, 3370–3378.
[9] Grossman, S.R., Perez, M., Kung, A.L., Joseph, M., Mansur, C., Xiao, Z.X., et al.
(1998) P300/MDM2 complexes participate in MDM2-mediated p53
degradation. Mol. Cell 2, 405–415.
[10] Hennies, H.C., Kornak, U., Zhang, H., Egerer, J., et al. (2008) Gerodermia
osteodys-plastica is caused by mutations in SCYL1BP1, a Rab-6 interacting
golgin. Nat. Genet. 40, 1410–1412.
[11] Jackson, P.K., Eldridge, A.G., Freed, E., Furstenthal, L., Hsu, J.Y., Kaiser, B.K., et al.
(2000) The lore of the RINGs: substrate recognition and catalysis by ubiquitin
ligases. Trends Cell Biol. 10, 429–439.
[12] Kurki, S., Peltonen, K., Latonen, L., Kiviharju, T.M., Ojala, P.M., Meek, D. and
Laiho, M. (2004) Nucleolar protein NPM interacts with HDM2 and protects
tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell
5, 465–475.
[13] Legube, G., Linares, L.K., Lemercier, C., Scheffner, M., Khochbin, S. and Trouche,
D. (2002) Tip60 is targeted to proteasome-mediated degradation by Mdm2
and accumulates after UV irradiation. EMBO J. 21, 1704–1712.
[14] Montes, O., Luna, R., Wagner, D.S. and Lozano, G. (1995) Rescue of early
embryonic lethality in MDM2-deﬁcient mice by deletion of p53. Nature 378,
203–206.
[15] Saxena, A., Rorie, C.J., Dimitrova, D., Daniely, Y. and Borowiec, J.A. (2006)
Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization.
Oncogene 25, 7274–7288.
[16] Shenoy, S.K., McDonald, P.H., Kohout, T.A. and Lefkowitz, R.J. (2001) Regulation
of receptor fate by ubiquitination of activated b2-adrenergic receptor and b-
arrestin. Science 294, 1307–1313.
[17] Weber, J.D., Kuo, M.L., Bothner, B., DiGiammarino, E.L., Kriwacki, R.W., Rousse,
M.F. and Sherr, C.J. (2000) Cooperative signals governing ARF-MDM2
interaction and nucleolar localization of the complex. Mol. Cell. Biol. 20,
2517–2528.
[18] Yogosawa, S., Miyauchi, Y., Honda, R., Tanaka, H. and Yasudaa, H. (2003)
Mammalian Numb is a target protein of Mdm2, ubiquitin ligase. Biochem.
Biophys. Res. Commun. 302, 869–872.
[19] Zhang, L., Li, J., Wang, C., Ma, Y. and Huo, K. (2003) A new human gene hntkl-
BP1 interacts with hpirh2. Biochem. Biophys. Res. Commun. 330, 293–297.
